Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6RD0

Human MMP12 catalytic domain in complex with AP280

Summary for 6RD0
Entry DOI10.2210/pdb6rd0/pdb
DescriptorMacrophage metalloelastase, ZINC ION, CALCIUM ION, ... (6 entities in total)
Functional Keywordsmmp12, inhibitors, catalytic domain, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight18253.12
Authors
Calderone, V.,Fragai, M.,Luchinat, C. (deposition date: 2019-04-12, release date: 2020-02-19, Last modification date: 2024-01-24)
Primary citationTsoukalidou, S.,Kakou, M.,Mavridis, I.,Koumantou, D.,Calderone, V.,Fragai, M.,Stratikos, E.,Papakyriakou, A.,Vourloumis, D.
Exploration of zinc-binding groups for the design of inhibitors for the oxytocinase subfamily of M1 aminopeptidases.
Bioorg.Med.Chem., 27:115177-115177, 2019
Cited by
PubMed Abstract: The oxytocinase subfamily of M1 aminopeptidases consists of three members, ERAP1, ERAP2 and IRAP that play several important biological roles, including key functions in the generation of antigenic peptides that drive human immune responses. They represent emerging targets for pharmacological manipulation of the immune system, albeit lack of selective inhibitors is hampering these efforts. Most of the previously explored small-molecule binders target the active site of the enzymes via strong interactions with the catalytic zinc(II) atom and, while achieving increased potency, they suffer in selectivity. Continuing our earlier efforts on weaker zinc(II) binding groups (ZBG), like the 3,4-diaminobenzoic acid derivatives (DABA), we herein synthesized and biochemically evaluated analogues of nine potentially weak ZBGs, based on differential substitutions of functionalized pyridinone- and pyridinethione-scaffolds, nicotinic-, isonicotinic-, aminobenzoic- and hydrazinobenzoic-acids. Crystallographic analysis of two analogues in complex with a metalloprotease (MMP-12) revealed unexpected binding topologies, consistent with the observed affinities. Our results suggest that the potency of the compounds as inhibitors of ERAP1, ERAP2 and IRAP is primarily driven by the occupation of active-site specificity pockets and their proper orientation within the enzymes.
PubMed: 31711716
DOI: 10.1016/j.bmc.2019.115177
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.9 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon